Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIb Clinical Trial to Evaluate the Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects

Next Previous
Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIb Clinical Trial to Evaluate the Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 03 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Esupaglutide alpha (Primary)
  • Indications Obesity
  • Focus Therapeutic Use
  • Acronyms ENLIGHT
  • Sponsors Yinnuo Pharmaceutical Technology

Most Recent Events

  • 03 Oct 2025 Last checked against ClinicalTrials.gov: US National Institutes of Health record.
  • 03 Sep 2025 Phase has been changed to II\III ,Addition of 1 Primary endpoint ,no. of patients has been increased. Number of arms have been increase to 9.
  • 03 Sep 2025 Planned number of patients changed from 200 to 992.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top